195 related articles for article (PubMed ID: 33000229)
1. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
[TBL] [Abstract][Full Text] [Related]
2. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Tanaka R; Squires MS; Kimura S; Yokota A; Nagao R; Yamauchi T; Takeuchi M; Yao H; Reule M; Smyth T; Lyons JF; Thompson NT; Ashihara E; Ottmann OG; Maekawa T
Blood; 2010 Sep; 116(12):2089-95. PubMed ID: 20548094
[TBL] [Abstract][Full Text] [Related]
3. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
4. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
Okabe S; Moriyama M; Gotoh A
Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
[TBL] [Abstract][Full Text] [Related]
5. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
7. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
8. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
9. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Shah M; Gallipoli P; Lyons J; Holyoake T; Jørgensen H
Blood Cells Mol Dis; 2012 Mar; 48(3):199-201. PubMed ID: 22325915
[No Abstract] [Full Text] [Related]
10. Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
Illert AL; Seitz AK; Rummelt C; Kreutmair S; Engh RA; Goodstal S; Peschel C; Duyster J; von Bubnoff N
PLoS One; 2014; 9(11):e112318. PubMed ID: 25426931
[TBL] [Abstract][Full Text] [Related]
11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
12. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
14. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
Podesta JE; Sugar R; Squires M; Linardopoulos S; Pearson AD; Moore AS
Leuk Res; 2011 Sep; 35(9):1273-5. PubMed ID: 21665275
[TBL] [Abstract][Full Text] [Related]
15. A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.
Long ZJ; Wang LX; Zheng FM; Chen JJ; Luo Y; Tu XX; Lin DJ; Lu G; Liu Q
Int J Oncol; 2015; 46(6):2488-96. PubMed ID: 25872528
[TBL] [Abstract][Full Text] [Related]
16. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
18. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
Jayanthan A; Cooper TM; Hoeksema KA; Lotfi S; Woldum E; Lewis VA; Narendran A
Leuk Lymphoma; 2013 Jul; 54(7):1505-16. PubMed ID: 23176524
[TBL] [Abstract][Full Text] [Related]
19. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]